Johnson & Johnson privately reached out to Covid-19 vaccine rivals to ask them to join an effort to study the risks of blood clots and speak with one voice about safety, but Pfizer Inc. and Moderna Inc. declined.
As concerns mounted last week over rare cases of blood clots, J&J asked AstraZeneca PLC as well as Pfizer and Moderna to join its efforts looking into the reports, people familiar with the matter said. J&J, through emails and phone calls, also sought to build an informal alliance to communicate the benefits and risks of the shots and address any concerns raised among the public by the blood-clot cases, some of the people said.
Six women who got J&J’s vaccine developed clots, and one died, out of more than seven million doses administered across the U.S., according to federal health officials. The specific adverse event hasn’t been reported by people who received the Pfizer and Moderna shots, the officials said.
Source: Wall Street Journal
Antibiotic Prescriptions Associated With COVID-19 Outpatient Visits Among Medicare Beneficiaries, April 2020 to April 2021
Outpatient Visits for COVID-19 and Associated Antibiotic Prescriptions Among Medicare Beneficiaries Aged 65 Years or Older, by Setting, US, April 2020 to April 2021. The volume of COVID-19 visits differed by setting: emergency department, 525 608 (45.8% of all visits); office, 295 983 (25.3%); telehealth, 260 261 (22.3%); and urgent care, 77 268 (6.6%).
Source: Journal of American Medical Association Network